Medical cannabis has been legal in the UK since 2018, after a high‑profile campaign led by two mothers who fought for lifesaving treatment for their children. Yet, years later, most patients who might benefit still cannot get it through the National Health Service (NHS).
This gap between law on paper and care in practice has left families confused and frustrated. Understanding why requires looking at how the law changed, what it actually allows, and why doctors and hospitals remain so cautious.
How medical cannabis became legal in the UK
The turning point came in 2018, when two families pushed the government to act.
According to detailed reporting by the Guardian, two mothers sought cannabis‑based medicines for their children, who suffered from severe, treatment‑resistant epilepsy. Conventional drugs had failed to control the children’s seizures. Overseas, doctors had prescribed cannabis‑derived products that appeared to reduce seizure frequency dramatically.
When UK authorities blocked access to these medicines, the mothers challenged the decision publicly and through official channels. Their cases drew national attention, highlighting that:
- The children’s seizures were frequent and dangerous.
- Other licensed medicines had been tried without success.
- Cannabis‑based products prescribed abroad appeared to help, based on the families’ accounts and the prescribing doctors’ assessments.
The public pressure, and the stark contrast between the children’s condition with and without the medicines, pushed ministers to review existing rules. In late 2018, the UK government reclassified certain cannabis‑based products, allowing specialist doctors to prescribe them in limited circumstances.
The legal change was widely reported at the time as a victory for the families and a breakthrough for patients with similar conditions.
What the 2018 legal change actually allows
The law did not open a broad, over‑the‑counter market for cannabis. Instead, it created a narrow medical route.
Based on the Guardian’s account of the reform, the key points are:
- Only specialist doctors can prescribe. These are typically hospital consultants, not general practitioners (GPs).
- Only “cannabis‑based products for medicinal use” are covered. These are specific formulations that meet quality and manufacturing standards, not general herbal cannabis.
- Prescribing is intended for severe conditions. The initial political debate focused on rare, treatment‑resistant epilepsy in children, though the law itself is broader.
In practice, that means a patient cannot simply ask a GP for medical cannabis. They must be referred to a specialist, who then has to decide whether a cannabis‑based medicine is appropriate and justifiable.
The mothers who campaigned for the change succeeded in securing that legal route. But the route is narrow and, as their later experience showed, difficult to use.
Why access remains so limited in practice
Despite the legal change, the Guardian’s reporting describes a system where prescriptions are rare and families still struggle to obtain the medicines they fought for.
Several factors, drawn from that reporting, help explain the gap:
1. Specialist doctors are reluctant to prescribe
Specialist doctors carry legal and professional responsibility for any prescription they issue. The Guardian account indicates that many are cautious about cannabis‑based medicines because:
- Evidence from large, controlled clinical trials is still limited for some conditions.
- Professional guidance, including from medical bodies, stresses caution and recommends prescribing only in very specific cases.
- Doctors fear criticism or regulatory scrutiny if they prescribe outside narrow guidelines.
As a result, even when the law allows a prescription, many specialists choose not to issue one.
2. NHS systems were not built around cannabis medicines
The Guardian reporting describes families encountering layers of NHS bureaucracy after the law changed. Though the medicine was technically legal, hospitals and local health bodies still had to decide whether to fund it.
In practice, this meant:
- Funding panels or committees assessing individual requests.
- Lengthy reviews of each case, even when a child had already responded well to the medicine.
- Unclear responsibility between national policy and local NHS decision‑makers.
For the two mothers at the centre of the story, this translated into repeated battles to keep their children’s prescriptions going, despite the legal change they had helped secure.
3. Limited UK‑licensed products
The Guardian account notes that only a small number of cannabis‑based medicines are formally licensed in the UK for specific conditions. When a medicine is licensed, it has gone through a full regulatory process, including large clinical trials.
The children in the reported cases were using products that did not always fit neatly into those licensed categories. That placed their prescriptions into a more complex area where doctors had to justify “off‑label” or unlicensed use, which is allowed in UK practice but more tightly scrutinised.
4. Policy caution after the legal change
Although the law shifted relatively quickly under public pressure, the Guardian reporting suggests that official guidance remained conservative. Medical bodies and health authorities emphasised that cannabis‑based medicines should be considered only when other treatments had failed and where there was at least some supporting evidence.
This cautious stance was meant to protect patients from poorly evidenced treatments. But for families whose children had already shown improvement on cannabis‑based medicines, it felt like a barrier that ignored their lived experience.
What this means for patients and families
For the two mothers whose cases drove the legal change, the outcome has been bittersweet, according to the Guardian report.
On one hand:
- They achieved a landmark shift: medical cannabis is now legal in the UK under defined conditions.
- Their children gained access to medicines that, in their view and in the view of the prescribing doctors, reduced life‑threatening seizures.
On the other hand:
- Access remains fragile, depending on individual doctors’ decisions and local NHS funding choices.
- Other families in similar situations still struggle to obtain prescriptions, even after the law changed.
The story illustrates a broader pattern in health policy: changing the law is only one step. Implementing that change across hospitals, clinics and professional practice can take years, especially when the treatment is politically sensitive and the evidence base is still developing.
How this differs from wider drug policy debates
The Guardian reporting focuses on medical use, not recreational cannabis. The mothers’ campaign was about specific, clinically guided treatments for severe epilepsy, not general legalisation.
That distinction matters because:
- The law that changed in 2018 applies only to medical products prescribed by specialists.
- Wider debates about recreational cannabis, criminal penalties or commercial markets are separate and were not the subject of the families’ campaign as described in the reporting.
Keeping those issues separate helps explain why the UK could legalise certain medical products while maintaining strict controls on other forms of cannabis.
Key takeaways for readers
From the Guardian’s detailed account of the two mothers’ fight, several clear points emerge:
- Medical cannabis is legal in the UK, but only in tightly defined ways. The 2018 change allows specialist doctors to prescribe certain cannabis‑based products.
- The change was driven by individual families. Two mothers, seeking to control their children’s severe epilepsy, pushed the government to act after being blocked from accessing medicines that appeared to help.
- Legalisation did not guarantee easy access. Doctors’ caution, limited licensed products and NHS funding processes mean prescriptions remain rare.
- Families still face case‑by‑case battles. Even after the law changed, the mothers described in the Guardian report had to keep pushing to secure and maintain treatment.
For readers trying to make sense of the apparent contradiction—legal but hard to get—the core explanation is that law, medical practice and health‑service systems do not move at the same speed. In this case, a rapid legal shift created an opening, but the everyday machinery of the NHS and professional medicine has been much slower to follow.
